1. U. S. Department of Health and Human Services, Food and Drug Administration, 21 CFR Part 58, Good Laboratory Practice Regulations; Final Rule. 1987.
http://www.fda.gov/downloads/ICECI/EnforcementActions/BioresearchMonitoring/ucm133730.pdf
. Accessed December 22, 2011.
2. Organisation for Economic Co-operation and Development, Environment Directorate, Chemicals Group and Management Committee. 1998. OECD Principles of Good Laboratory Practice. ENV/MC/CHEM(98)17.
http://www.oecd.org/officialdocuments/displaydocumentpdf?cote=env/mc/chem(98)17&doclanguage=en
. Accessed December 22, 2011.
3. Japan, Ministry of Health, Labor and Welfare. Ordinance No. 21. March 26, 1997.
4. Whitmire ML, Bryan P, Henry TR, Holbrook J, Lehman P, Mollitor T, et al. Nonclinical dose formulation analysis method validation and sample analysis. AAPS J. 2010;12(4):628–34. doi:
10.1208/s12248-010-9226-9
.
5. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production. 2006.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070287.pdf
. Accessed December 22, 2011.